We are thrilled to share the exciting news of our latest achievement in securing European funding. The consortium led by Prof. Pilar Sanchez Gomez from Unidad de Neurooncología, Instituto de Salud Carlos III, Majadahonda, Spain, has successfully obtained support for the project titled "Reaching the heterogeneous vascular landscape of glioblastoma with multifunctional nanomedicines." The Transcan-3 grant application was not only approved but also activated in late 2023.

The "ReachGLIO" project is poised to pave the way for a groundbreaking pre-clinical framework, essential for the development of a novel and effective therapy targeting high-grade gliomas. The approach involves the utilization of dual-targeted nanoparticles loaded with potent anti-cancer drugs. Furthermore, the project explores the potential synergy of this approach when combined with peptide-guided tumor necrosis factor.

This success marks a significant milestone in our pursuit of advancing cancer therapeutics. The funded project will contribute valuable insights and data, bringing us one step closer to a more effective treatment for glioblastomas. We express our gratitude to the Transcan-3 grant program for recognizing the potential impact of our research and supporting our efforts to combat high-grade gliomas.